The Search for Biomarkers of Metastatic Seminoma

Ruf, Christian; Khalili-Harbi, N.; Sachs, Sharona; Isbarn, Hendrik; Wagner, Walter; Matthies, Cord; Meineke, V.; Fisch, Margit; Chun, Felix K.-H.; Abend, Michael

doi:10.1016/j.juro.2013.04.022

Cited by 14 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to previous studies performed on larger groups ( n =527), the association of tumour size with metastasis status appeared significant, but the discriminatory capacity of this and other clinical–histological parameter (e.g. tumour/testicular volume, tumour length) did not exceed a concordance of 65% (Ruf et al , 2013b), indicating a limited discrimination ability of tumour size in contrast to the small RNAs examined in this study. Moreover, according to our experiences RNA examinations should be performed in cryopreserved tissues or using solvents to protect RNA.…”

Section: Discussioncontrasting

confidence: 45%

“…In truly non-metastasised clinical stage I (cSI), patients are cured by orchidectomy alone; however, despite modern staging and classification procedures, up to 30% of cSI seminoma patients bear occult metastasis in primary staging and relapse after orchidectomy alone (Krege et al , 2008; Albers et al , 2012). Until now, no reliable biological parameters exist and the clinical parameter shows a concordance of 65% only in differentiating occult metastasised stages from non-metastasised seminoma (Ruf et al , 2013b). Identification of occult metastasised patients is one of the main goals to prevent toxicity (e.g.…”

mentioning

confidence: 99%

“…Recent publications facilitate the idea of certain demographic/clinical histological risk factors to be associated with both detectable and occult seminoma metastasis (Warde et al , 1997, 2002; Valdevenito et al , 2007; Krege et al , 2008; Albers et al , 2012; Ruf et al , 2013b). We also showed both metastasis subtypes to be indistinguishable on the transcriptional level using a whole genome screening, suggesting that they are not representing different metastasis subtypes (Ruf et al , 2014).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS

et al. 2014

View full text Add to dashboard Cite

Background:We aimed to better discriminate (occult) metastasised from non-metastasised seminoma based on transcriptional changes of small RNAs in the primary tumour.Methods:Total RNAs including small RNAs were isolated from five testicular tumours of each, lymphogenic, occult and non-metastasised patients. Next-generation sequencing (SOLID, Life Technologies) was used to examine transcriptional changes. Small RNAs showing ⩾50 reads and a significant ⩾2-fold difference using non-metastasised tumours as the reference group were examined in univariate logistic regression analysis and combinations of two small RNAs were further examined using support vector machines.Results:On average, 1.3 × 107, 1.4 × 107 and 1.7 × 107 small RNA reads were detectable in non-metastasised, occult and lymphogenic metastasised seminoma, respectively, of which 30–32% remained after trimming. Between 59 and 68% represented annotated reads and between 8.6 and 11% were annotated small RNA tags. Of them, 137 small RNAs showed>50 reads and a two-fold difference to the reference. In univariate analysis, 32–38 small RNAs significantly discriminated lymphogenic/occult from non-metastasised seminoma, and among these different comparisons, it were the same small RNAs in 51–88%. Many combinations of two of these small RNAs allowed a complete discrimination of metastasised from non-metastasised seminoma irrespective of the metastasis subtype.Conclusions:Metastasised and non-metastasised seminoma can be completely discriminated with a combination of two small RNAs.

show abstract

Section: Discussioncontrasting

confidence: 45%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Por otra parte, los niveles elevados de AFP y HGC, que son marcadores tumorales sanguíneos, orientan sobre la existencia, diseminación y recaída de los tumores germinales 12 . En nuestro paciente se encontraron niveles elevados de HGC, pero la AFP fue normal, lo que reforzó el diagnós-tico mencionado con antelación.…”

Section: Discussionunclassified

Tumor extragonadal de células germinales con fenómeno de burned-out testicular

Ulloa-Ortiz¹,

Garza-Garza²,

Martinez³

et al. 2019

GAMO

View full text Add to dashboard Cite

“…Since 2014, the EAU guidelines endorse active surveillance as a level A recommendation for stage 1 seminoma (9). The effect of these risk factors (rete testis invasion and tumor size) on oncological outcomes is still debated (14,15,16,17).…”

Section: Discussionmentioning

confidence: 99%

A Rare Tumor: Small Cell Prostate Carcinoma Case Report

Aydın¹,

Bolat²,

Taşlı³

et al. 2018

uob

View full text Add to dashboard Cite

IntroductionTesticular cancer accounts for 1-1.5% of all cancers in men and 5% of male urological malignancies. It is usually seen between the ages of 15 and 35. In the USA, it is the most common malignancy among men aged 20-40 years and the second most common malignancy after leukemia among adolescents aged 15-19 years. The prevalence of bilateral germ cell tumor (GCT) is 2.5%, with 0.6% of these being synchronous tumors and 1.9% being metachronous contralateral tumors (1).The vast majority (90-95%) of testicular tumors are GCTs. The most common histological type of GCT is seminoma (55%), which peaks between the ages of 30-40 years. Non-seminomas account for 40% and peak between the ages of 20-30 years (2). Stage 1 seminomas comprise the majority (80-85%) of GCTs diagnosed in daily practice (3,4). The 10-year overall Objective: Treatment modalities applied after orchiectomy in early-stage germ cell tumors (GCTs) include significant changes in each new study. In this study we reevaluated the treatment approaches used in our hospital between 2010-2014 according to current guidelines. Materials and Methods: We retrospectively evaluated the oncologic treatments and follow-up data of 32 patients who underwent radical orchiectomy between January 2010 and December 2014 due to testicular tumor and were diagnosed with early stage GCT in the Urology Clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital of University of Health Sciences. Results: Of 19 patients diagnosed with stage 1 seminomas, 3 patients in the low risk group were followed. Of 4 patients who received single-dose carboplatin therapy, 2 were at low risk and 2 were at high risk. Therefore, 2 patients at low-risk had overtreatment. Twelve patients were treated with radiotherapy (RT) that was no longer recommended in guidelines after 2014. Two patients in the low risk group of stage 1 non-seminoma were followed. One of them had recurrence at 12 months, and received 3 cycles of bleomycin + etoposide + cisplatin (BEP) according to current guidelines. Four patients with stage 1 non-seminoma underwent 2 cycles of BEP because they were considered at high risk. These patients are now recommended to receive 1 cycle BEP according to the current guidelines. While 4 patients with stage 1 mixed GCT were followed because of low risk, one patient was administered 2 cycle of BEP based on the old guidelines, at that time because of high risk. In the seminoma group that was administered RT, acute myeloblastic leukemia and oligospermia toxicity were detected, but these were not observed in the carboplatin group. One of high-risk non-seminoma patients who received 2 doses of BEP developed Myelodysplastic syndrome. Conclusion: Early-stage GCTs have high cancer-specific and overall survival rates with appropriate treatment approaches. Although there are still controversial issues regarding their management, treatment approaches are changing with each study. Therefore, it is crucial to remain informed about current international guidelines and...

show abstract

The Search for Biomarkers of Metastatic Seminoma

Abstract: New biomarkers of metastatic seminoma were identified and previously described risk factors were validated. Further prospective studies of these novel parameters are warranted to verify our findings and to explore a potential use for detecting occult metastases.

Cited by 14 publications

References 14 publications

Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS

Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS

Tumor extragonadal de células germinales con fenómeno de burned-out testicular

A Rare Tumor: Small Cell Prostate Carcinoma Case Report

Contact Info

Product

Resources

About